Migraine as an inflammatory disorder

Inflammation is a localized response designed to protect tissues against infection, injury, or disease. The inflammatory response acts to destroy, dilute, or wall off (sequester) both the injurious agent and the injured area. The production and release of chemical agents by cells in the affected tissue result in the four well-known signs of Celsus: pain (dolor), heat (calor), redness (rubor), and swelling (tumor), to which Galen later added loss of function (functio laesa). Histologically, inflammation is characterized by a complex series of events. These include the following: dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the inflammatory focus. Although pain and inflammation usually go hand in hand, migraine has not classically been considered an inflammatory disease, possibly because it is not obviously associated with heat, redness, and swelling. Instead, a vascular etiology was proposed on the basis of a report that ergotamine tartrate alleviates pain and reduces the amplitude of temporal artery pulsation in migraineurs,1 a small but significantly increased risk for strokes,2 association with vascular malformations,3 and genetic disorders such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).4 For most of the twentieth century, the prevailing theory of migraine held that pain results from an abnormal dilatation of intracranial blood vessels, leading to mechanical excitation of sensory fibers that innervate these vessels. This “vascular” theory, however, has never been validated. No differences in blood flow velocity exist in vertebral and middle cerebral arteries during and outside migraine attacks,5 and a consistent relationship between vessel caliber, cerebral blood flow, and headache has not been established.6 In recent years, accumulating evidence has shifted the emphasis away from vascular smooth muscle and toward mechanisms related to inflammation within cephalic …

[1]  H. Chabriat,et al.  Migraine with aura and brain magnetic resonance imaging abnormalities in patients with CADASIL. , 2004, Archives of neurology.

[2]  M. Møller,et al.  Origin of PACAP-immunoreactive Nerve Fibers Innervating the Subarachnoidal Blood Vessels of the Rat Brain , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  J. Olesen,et al.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. , 2004, The New England journal of medicine.

[4]  R. Ravid,et al.  EP4 prostanoid receptor‐mediated vasodilatation of human middle cerebral arteries , 2004, British journal of pharmacology.

[5]  R. Burstein,et al.  Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization , 2004, Annals of neurology.

[6]  W. Willis,et al.  The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin , 2003, Pain.

[7]  K. Welch Stroke and migraine--the spectrum of cause and effect. , 2003, Functional neurology.

[8]  H. Diener Rpr100893, A Substance-P Antagonist, is Not Effective in the Treatment of Migraine Attacks , 2003, Cephalalgia : an international journal of headache.

[9]  M. Moskowitz,et al.  Nuclear factor-kappaB as a molecular target for migraine therapy. , 2003, Annals of neurology.

[10]  L. May,et al.  Efficacy and Safety of Acetaminophen and Naproxen in the Treatment of Tension-Type Headache. A Randomized, Double-Blind, Placebo-Controlled Trial , 2002, Cephalalgia : an international journal of headache.

[11]  Y. Sugimoto,et al.  Prostanoid receptor subtypes. , 2002, Prostaglandins & other lipid mediators.

[12]  M. Weber,et al.  Efficacy of oral ketoprofen in acute migraine: A double-blind randomized clinical trial , 2002, Neurology.

[13]  M. Boehme,et al.  A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects , 2002, Rheumatology International.

[14]  J. Olesen,et al.  Cgrp May Play A Causative Role in Migraine , 2002, Cephalalgia : an international journal of headache.

[15]  Andrew K. Dunn,et al.  Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model , 2002, Nature Medicine.

[16]  M. Moskowitz,et al.  Delayed inflammation in rat meninges: implications for migraine pathophysiology. , 2001, Brain : a journal of neurology.

[17]  W. Feniuk,et al.  Characterization of the prostanoid receptor types involved in mediating calcitonin gene‐related peptide release from cultured rat trigeminal neurones , 2001, British journal of pharmacology.

[18]  R. Couture,et al.  Kinin receptors in pain and inflammation. , 2001, European journal of pharmacology.

[19]  L. Edvinsson Sensory Nerves in Man and Their Role in Primary Headaches , 2001, Cephalalgia : an international journal of headache.

[20]  E. Nelson,et al.  Efficacy of Nonprescription Doses of Ibuprofen for Treating Migraine Headache. A Randomized Controlled Trial , 2001, Headache.

[21]  Q. Ma,et al.  Co-localization of 5-HT1B/1D/1F receptors and glutamate in trigeminal ganglia in rats , 2001, Neuroreport.

[22]  J. Korf,et al.  Migraine and Function of the Immune System: A Meta-Analysis of Clinical Literature Published Between 1966 and 1999 , 2001, Cephalalgia : an international journal of headache.

[23]  Q. Ma,et al.  Colocalization of CGRP with 5‐HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats , 2001, The European journal of neuroscience.

[24]  R. Hargreaves,et al.  Neurogenic inflammation in the context of migraine , 2001, Microscopy research and technique.

[25]  R. Burstein,et al.  Deconstructing migraine headache into peripheral and central sensitization , 2001, Pain.

[26]  A. Rizzi,et al.  Classification of Kinin Receptors , 2001, Biological chemistry.

[27]  D. Čížková,et al.  The role of nitric oxide in nociception , 2000, Current review of pain.

[28]  V. Gallai†,et al.  Nitric Oxide Metabolites, Prostaglandins and Trigeminal Vasoactive Peptides in Internal Jugular Vein Blood During Spontaneous Migraine Attacks , 2000, Cephalalgia : an international journal of headache.

[29]  S. Bingham,et al.  Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia , 2000, Nature.

[30]  R. Lipton,et al.  Evaluation of a Novel Solubilized Formulation of Ibuprofen in the Treatment of Migraine Headache: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study , 2000, Cephalalgia : an international journal of headache.

[31]  D. Julius,et al.  Capsaicin receptor in the pain pathway. , 2000, Japanese journal of pharmacology.

[32]  A I Basbaum,et al.  Impaired nociception and pain sensation in mice lacking the capsaicin receptor. , 2000, Science.

[33]  E. Hamel,et al.  No contractile effect for 5‐HT1D and 5‐HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery , 2000, British journal of pharmacology.

[34]  A. A. Parsons,et al.  Effects of sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion in the rat. Implications for antimigraine mechanisms , 1999, Brain Research.

[35]  H. Diener Efficacy and Safety of Intravenous Acetylsalicylic Acid Lysinate Compared To Subcutaneous Sumatriptan and Parenteral Placebo in the Acute Treatment of Migraine. A Double-Blind, Double-Dummy, Randomized, Multicenter, Parallel Group Study , 1999 .

[36]  H. Handwerker,et al.  Nociceptive neurons in the rat caudal trigeminal nucleus respond to blood plasma perfusion of the subarachnoid space: the involvement of complement , 1999, Pain.

[37]  K. Messlinger,et al.  Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro , 1999, Neuroscience.

[38]  Effect of a nitric oxide donor on nitroxergic nerve fibers in the rat dura mater , 1999, Neuroscience Letters.

[39]  H. Diener Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. , 1999, Cephalalgia : an international journal of headache.

[40]  R. Egan,et al.  Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. , 1998, The Journal of pharmacology and experimental therapeutics.

[41]  C. Waeber The Role of 5-HT1B/1D Receptors in the Treatment of Migraine , 1998, CNS Spectrums.

[42]  S. Moore,et al.  Regulation of prostaglandin H synthase‐2 expression in cerebromicrovascular smooth muscle by serum and epidermal growth factor , 1998, Journal of cellular physiology.

[43]  A. Basbaum,et al.  The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli , 1998, Neuron.

[44]  A. Rizzi,et al.  Bradykinin receptors and their antagonists. , 1998, European journal of pharmacology.

[45]  P. Bonaventure,et al.  5HT1B and 5HT1D receptor mRNA differential co‐localization with peptide mRNA in the guinea pig trigeminal ganglion , 1998, Neuroreport.

[46]  R. Burstein,et al.  Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. , 1998, Journal of neurophysiology.

[47]  J. Olesen,et al.  Nitric Oxide Synthase Inhibition: A New Principle in the Treatment of Migraine Attacks , 1998, Cephalalgia : an international journal of headache.

[48]  J. Saper,et al.  Ineffectiveness of Neurokinin-1 Antagonist in Acute Migraine , 1997, Cephalalgia : an international journal of headache.

[49]  R. Hargreaves,et al.  Sumatriptan Inhibits Neurogenic Vasodilation of Dural Blood Vessels in the Anaesthetized Rat—Intravital Microscope Studies , 1997, Cephalalgia : an international journal of headache.

[50]  C. Woolf,et al.  Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α , 1997, British journal of pharmacology.

[51]  L. Phebus,et al.  The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. , 1997, Life sciences.

[52]  M. Perren,et al.  The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system , 1997, Regulatory Peptides.

[53]  M. Hildebrand Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients , 1997, European Journal of Clinical Pharmacology.

[54]  R. Burstein,et al.  Sensitization of meningeal sensory neurons and the origin of headaches , 1996, Nature.

[55]  P. Séguéla,et al.  Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. , 1996, Molecular pharmacology.

[56]  C. Tassorelli,et al.  NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration , 1995, Brain Research.

[57]  M. T. Brewer,et al.  Mechanisms of tumor necrosis factor-α (TNF-α) hyperalgesia , 1995, Brain Research.

[58]  S. Brain,et al.  The modulation of the increase in rat facial skin blood flow observed after trigeminal ganglion stimulation. , 1995, European journal of pharmacology.

[59]  C. Woolf,et al.  Contribution of interleukin‐1β to the inflammation‐induced increase in nerve growth factor levels and inflammatory hyperalgesia , 1995, British journal of pharmacology.

[60]  S. McMahon,et al.  Immunocytochemical Localization of trkA Receptors in Chemically Identified Subgroups of Adult Rat Sensory Neurons , 1995, The European journal of neuroscience.

[61]  A. Dray,et al.  Kinins and kinin receptors in the nervous system , 1995, Neurochemistry International.

[62]  S. Brain,et al.  Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide , 1995, Brain Research.

[63]  M. T. Brewer,et al.  Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. , 1995, Brain research.

[64]  F. Sundler,et al.  Pituitary adenylate cyclase activating polypeptide expression in sensory neurons , 1994, Neuroscience.

[65]  P. Goadsby,et al.  Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation of the cat. , 1994, Journal of the autonomic nervous system.

[66]  M. Perkins,et al.  The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine‐induced mechanical hyperalgesia in the rat , 1994, British journal of pharmacology.

[67]  S. Maier,et al.  Characterization of cytokine-induced hyperalgesia , 1994, Brain Research.

[68]  M. Moskowitz,et al.  Blockade by oral or parenteral RPR 100893 (a non‐peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea‐pig dura mater and conjunctiva , 1994, British journal of pharmacology.

[69]  S. Narumiya,et al.  International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. , 1994, Pharmacological reviews.

[70]  D. Haas Migraine and Intracranial Vascular Malformations , 1994, Headache.

[71]  H. Holthusen,et al.  Nitric oxide evokes pain in humans on intracutaneous injection , 1994, Neuroscience Letters.

[72]  S. Ferreira,et al.  Bradykinin initiates cytokine‐mediated inflammatory hyperalgesia , 1993, British journal of pharmacology.

[73]  G. Jonakait Neural—immune interactions in sympathetic ganglia , 1993, Trends in Neurosciences.

[74]  J. Olesen,et al.  Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. , 1993, Neuroreport.

[75]  P. Goadsby,et al.  The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats , 1993, Annals of neurology.

[76]  M. Moskowitz,et al.  Neurovascular and molecular mechanisms in migraine headaches. , 1993, Cerebrovascular and brain metabolism reviews.

[77]  Z. Huang,et al.  UK-14,304, R(-)-alpha-methyl-histamine and SMS 201-995 block plasma protein leakage within dura mater by prejunctional mechanisms. , 1992, European journal of pharmacology.

[78]  M. Moskowitz,et al.  Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. , 1992, Circulation research.

[79]  J. Olesen,et al.  Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: Comparison with cerebral and temporal arteries , 1992, Peptides.

[80]  M. Moskowitz,et al.  Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation , 1992, Neuroscience.

[81]  A. Denman Cellular and Molecular Immunology , 1992 .

[82]  M. Ferrari,et al.  Blood Flow Velocities in the Vertebrobasilar System During Migraine Attacks a Transcranial Doppler Study , 1992, Cephalalgia : an international journal of headache.

[83]  M. Moskowitz Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. , 1992, Trends in pharmacological sciences.

[84]  F. Cunha,et al.  The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. , 1992, British journal of pharmacology.

[85]  M. Moskowitz,et al.  Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells , 1991, Neuroscience.

[86]  P. Goadsby,et al.  Vasoactive peptide release in the extracerebral circulation of humans during migraine headache , 1990, Annals of neurology.

[87]  P. Barnes,et al.  Modulation of neurogenic inflammation: novel approaches to inflammatory disease. , 1990, Trends in pharmacological sciences.

[88]  E. Whalley,et al.  Cerebrovascular effects of prostanoids: in-vitro studies in feline middle cerebral and basilar artery. , 1989, Prostaglandins.

[89]  A. A. Parsons,et al.  Effects of Prostanoids on Human and Rabbit Basilar Arteries Precontracted In Vitro , 1989, Cephalalgia : an international journal of headache.

[90]  J. O. Tuca,et al.  Increase in PGE2 and TXA2 in the Saliva of Common Migraine Patients. Action of Calcium Channel Blockers , 1989, Headache.

[91]  R. Coggeshall,et al.  Peptide immunoreactivity of unmyelinated primary afferent axons in rat lumbar dorsal roots. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[92]  M. Massobrio,et al.  Relevance of Prostaglandins in True Menstrual Migraine , 1989, Headache.

[93]  M. Moskowitz,et al.  Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headaches , 1988, Annals of neurology.

[94]  S. Ferreira,et al.  Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue , 1988, Nature.

[95]  K. Hongo,et al.  Effect of removal of the endothelium on vasocontraction in canine and rabbit basilar arteries. , 1988, Journal of neurosurgery.

[96]  J. Olesen,et al.  Delayed hyperemia following hypoperfusion in classic migraine. Single photon emission computed tomographic demonstration. , 1988, Archives of neurology.

[97]  P. Goadsby,et al.  Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system , 1988, Annals of neurology.

[98]  M. Moskowitz,et al.  Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[99]  I. Kanazawa,et al.  Regional distribution of substance P, neurokinin α and neurokinin β in rat spinal cord, nerve roots and dorsal root ganglia, and the effects of dorsal root section or spinal transection , 1985, Brain Research.

[100]  P. Emson,et al.  Coexistence of calcitonin gene-related peptide and substance P-like peptide in single cells of the trigeminal ganglion of the rat: immunohistochemical analysis , 1985, Brain Research.

[101]  R. Peatfield,et al.  The Effect of Infused Prostacyclin in Migraine and Cluster Headache , 1981, Headache.

[102]  E. Melamed,et al.  NEUROTRANSMITTERS AND THE FIFTH CRANIAL NERVE: IS THERE A RELATION TO THE HEADACHE PHASE OF MIGRAINE? , 1979, The Lancet.

[103]  J. Charlesworth,et al.  COMPLEMENT ACTIVATION IN MIGRAINE , 1977, The Lancet.

[104]  L. Ekelund,et al.  Clinical and metabolic effects of different doses of prostaglandin E1 in man. Prostaglandin and related factors. , 2009, Acta medica Scandinavica.

[105]  H. Wolff,et al.  MECHANISM OF MIGRAINE HEADACHE AND ACTION OF ERGOTAMINE TARTRATE , 1938 .